The MAs are not irrelevant — 200 SMA at $466.57 signals institutional sellers above that level, and the 31x forward multiple means the market is correctly anticipating deceleration not yet in the data.

• 200 SMA at $466.57
• Procedure growth: Q3 2025 at 11%, Q1 2026 at 14.6%, Q2 2026 at 18.5%
• Forward P/E: 30.81x
• $12.07 forward EPS implies 38.5% growth from $8.71 TTM
• Realistic EPS if revenue slips to 14%, margins flat, buybacks moderate: ~$11.50
• Forward P/E at realistic EPS: 32.3x (not 30.8x)
• Through-cycle EPS if competitive pressure materializes: $10.50-$10.90
• Forward P/E at through-cycle EPS: 34-35x

↩ rebuts: “Bull's argument that lagging indicators are irrelevant and that the price-fundamental divergence represents a buying opportunity.”

Post-July volume pattern is lack of conviction, not absorption — the stock is stuck waiting for a catalyst to break lower.

• July 17 selling climax: 11.56M shares
• Post-July volume pattern: 1.7M-3M on most days
• August 13-14 high at $401.27 made on volume 70% below selling climax volume
• August 19 attempt rejected at $397.72 on weak volume
• Stock drift between $360 and $400 since late July on average volume

↩ rebuts: “Bull's claim that volume shows absorption and that July 17 was a selling climax with subsequent sellers exhausted.”

RSI at 45 is the resting heart rate of a stock in a downtrend — not bullish basing but bearish consolidation likely to break below 30 on decisive downside.

• RSI at 45
• RSI oscillating in 40-55 range since mid-August
• No push above 55-60 on follow-through buying
• In healthy basing: series of higher lows (30, 35, 40, 45, 50)
• Actual pattern: oscillation without decisive push higher — bearish consolidation

↩ rebuts: “Bull's claim that sub-oversold RSI at 45 means selling pressure has been worked off.”

Medtronic's competitive threat is credible and underappreciated — the relevant comparison is surgical robotics R&D vs surgical robotics R&D, not total R&D, and Hugo's data flywheel erodes Intuitive Surgical's clinical moat with every procedure.

• Intuitive Surgical TTM FCF: $2.62B
• Medtronic surgical robotics investment: $700M
• Medtronic has 10x the hospital relationships across multiple product lines
• Hugo has CE Mark and FDA clearances — commercial, not development
• Medtronic is $110B+ medical device conglomerate able to absorb Hugo losses for years
• Forward P/E comparison: Intuitive Surgical 30.81x, Stryker ~26x, Medtronic ~14x, Boston Scientific ~22x, Abbott ~21x, Edwards Lifesciences ~24x
• Intuitive Surgical is the most expensive stock in the entire medical device universe after a 34% drawdown

↩ rebuts: “Bull's dismissal of Medtronic based on scale gap, installed-base moat, and 'already priced in' arguments.”

Downside is unimpeded while upside is gated by multiple resistance levels — the path from $372 to $466 requires passing through $383, $407, and $440 as overhead resistance.

• Break below $358 Bollinger band, next stop $345: -7.3% from current
• Break below $345, next stop $332: -10.7% from current
• Break below $332, next stop $300: -19.3% from current
• Stress scenario (Medtronic Hugo beat + multiple compression to 14x MDT-like forward P/E on $12 forward EPS): ~$170-180: -50%+
• Reclaim 50 SMA at $383: +3.0%
• Break above upper Bollinger at $407: +9.4%
• 200 SMA retest at $466: +25.3% (requires macro cooperation, competitive narrative resolution, and execution against elevated consensus estimates — sequentially with no missteps)

↩ rebuts: “Bull's framing of the risk/reward as asymmetric in favor of longs with 10-15% downside and 20-25% upside.”

The stop at $358 is exactly the Bollinger lower band — a knife's edge with insufficient cushion for a stock with 3.2% daily ranges.

• Current price: ~$372
• Stop at $358
• ATR: $11.89
• Daily range: 3.2%
• Stop cushion: $14, or 1.2x ATR (not enough cushion)

↩ rebuts: “Bull's framing of $14 stop as 'tight' when it is the precise Bollinger lower band that, if broken, opens accelerated downside.”

Macro tailwinds are consensus expectations already priced; the real asymmetric risk is the 'no landing' scenario where inflation re-accelerates and real rates rise, crushing long-duration equities.

• Beta: 1.46 (a 10% S&P correction takes Intuitive Surgical down 14-15%)
• Healthcare equipment outperformed S&P by 13.3pp over 6 months
• Intuitive Surgical has UNDERPERFORMED its own sector during that period
• This is competitive de-rating, not sector mean reversion setup
• A 100bps move higher in real rates would compress Intuitive Surgical's multiple by 15-20%
• Hospital capex is procyclical and exposed to labor cost spikes, commercial real estate pressure, and reimbursement tightening
• 2008-2009 hospital capex collapsed by 20%+ with material impact on procedure volumes

↩ rebuts: “Bull's citing of 89% no-cut probability and 8% recession probability as supportive macro tailwinds.”

Aggressive buybacks at potentially elevated valuations can mask business deterioration; the $5.2B net cash position with no debt signals management caution about the competitive landscape, not confidence.

• $3.7B buybacks in last four quarters
• $5.2B net cash position with no debt
• $133B market cap
• Buybacks are ~2.8% of market cap annually — not enough to overcome systematic selling pressure in a downtrend
• If moat were truly impregnable, management would lever up or do M&A rather than sit on cash and slowly buy back stock

↩ rebuts: “Bull's use of buybacks as a bullish capital return argument.”

The Ion platform is unproven at scale, procedure growth is cyclical and correlated with hospital capex, the forward EPS estimate is the ceiling not the floor, and the stock has failed every attempt to confirm a bottom since mid-July.

• Ion commercial ramp is early; lung-biopsy market is competitive (Bronvus, Auris Health legacy)
• Procedure volumes correlated with hospital capex cycles, insurance reimbursement, and consumer healthcare spending
• 2008-2009 hospital capex collapsed 20%+
• July 23 low ($332) → August 12 high ($401): failed
• August 19 retest ($397.72): failed
• Every bounce attempt since mid-July stalled before the 50 SMA
• Zero Reddit mentions across WSB, stocks, and investing subreddits in the past week — absence of retail demand cushion

↩ rebuts: “Bull's positive framing of Ion as a growth vector and procedure growth sustainability.”